Literature DB >> 8787670

Detection of monoclonal microsatellite alterations in atypical breast hyperplasia.

C L Rosenberg1, A de las Morenas, K Huang, L A Cupples, D V Faller, P S Larson.   

Abstract

Atypical hyperplastic (AH) breast lesions are currently classified and treated as benign proliferative disorders, but their presence is associated with a four- to fivefold increased risk of developing breast cancer. Currently, it is not known if an AH lesion is a marker of increased risk, or is itself a premalignant lesion. To investigate this question, we used a series of 15 microsatellite loci to analyze 15 separate AH lesions microdissected from the archived pathology specimens of subjects with no coincident or previous breast malignancy. We found that a significant subset (6/15, or 40%) of these AH lesions demonstrated evidence of monoclonal microsatellite alterations, both length variation and allele loss. These monoclonal alterations suggest that the AH lesion has already undergone genetic changes conferring a growth advantage. Thus, these AH lesions may actually be early neoplasms. We also noted that monoclonality characterized AH lesions in younger as compared with older women (44 vs. 59 yrs, P < 0.05) and that a subset of monoclonal lesions (4/6) demonstrated microsatellite alterations at more than one locus, suggesting that an undetermined type of genetic instability may play a role early in the development of abnormal breast proliferations. These findings contribute to our understanding of the pathogenesis of AH lesions and may have implications regarding their relationship to breast tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787670      PMCID: PMC507529          DOI: 10.1172/JCI118890

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

Review 1.  CYSTIC DISEASE OF THE BREAST: RELATIONSHIP TO CARCINOMA.

Authors:  H H DAVIS; M SIMONS; J B DAVIS
Journal:  Cancer       Date:  1964-08       Impact factor: 6.860

2.  Atypical hyperplastic lesions of the female breast. A long-term follow-up study.

Authors:  D L Page; W D Dupont; L W Rogers; M S Rados
Journal:  Cancer       Date:  1985-06-01       Impact factor: 6.860

3.  Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up.

Authors:  N Krieger; R A Hiatt
Journal:  Am J Epidemiol       Date:  1992-03-15       Impact factor: 4.897

4.  Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia.

Authors:  W D Dupont; D L Page
Journal:  Hum Pathol       Date:  1989-08       Impact factor: 3.466

5.  Clues to the pathogenesis of familial colorectal cancer.

Authors:  L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

6.  A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast.

Authors:  F A Tavassoli; H J Norris
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

7.  A prospective study of the development of breast cancer in 16,692 women with benign breast disease.

Authors:  C L Carter; D K Corle; M S Micozzi; A Schatzkin; P R Taylor
Journal:  Am J Epidemiol       Date:  1988-09       Impact factor: 4.897

8.  A prospective study of benign breast disease and the risk of breast cancer.

Authors:  S J London; J L Connolly; S J Schnitt; G A Colditz
Journal:  JAMA       Date:  1992-02-19       Impact factor: 56.272

9.  Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation.

Authors:  R C Allen; H Y Zoghbi; A B Moseley; H M Rosenblatt; J W Belmont
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

View more
  8 in total

1.  A developmental hypothesis to explain the multicentricity of breast cancer.

Authors:  C R Sharpe
Journal:  CMAJ       Date:  1998-07-14       Impact factor: 8.262

Review 2.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

3.  Microsatellite abnormalities in plasma of patients with breast carcinoma: concordance with the primary tumour.

Authors:  F Mayall; S Fairweather; R Wilkins; B Chang; R Nicholls
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

4.  Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas.

Authors:  C Washington; F Dalbègue; F Abreo; J K Taubenberger; J H Lichy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  Genetically abnormal clones in histologically normal breast tissue.

Authors:  P S Larson; A de las Morenas; L A Cupples; K Huang; C L Rosenberg
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

Review 6.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

7.  Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas.

Authors:  Pamela S Larson; Antonio de las Morenas; Sheila R Bennett; L Adrienne Cupples; Carol L Rosenberg
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

8.  Intraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer?

Authors:  Leopoldo Costarelli; Domenico Campagna; Maria Mauri; Lucio Fortunato
Journal:  Int J Surg Oncol       Date:  2012-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.